B. Metzler seel. Sohn & Co. AG Has $14.48 Million Stake in Amgen Inc. $AMGN

B. Metzler seel. Sohn & Co. AG lowered its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 14.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,311 shares of the medical research company’s stock after selling 8,507 shares during the quarter. B. Metzler seel. Sohn & Co. AG’s holdings in Amgen were worth $14,480,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Rathbones Group PLC raised its holdings in Amgen by 1.5% in the 3rd quarter. Rathbones Group PLC now owns 13,129 shares of the medical research company’s stock valued at $3,705,000 after acquiring an additional 193 shares in the last quarter. Vinva Investment Management Ltd grew its holdings in shares of Amgen by 21.5% during the 3rd quarter. Vinva Investment Management Ltd now owns 44,908 shares of the medical research company’s stock worth $12,303,000 after purchasing an additional 7,958 shares in the last quarter. Parallel Advisors LLC increased its position in shares of Amgen by 6.2% in the third quarter. Parallel Advisors LLC now owns 10,407 shares of the medical research company’s stock worth $2,937,000 after purchasing an additional 610 shares during the period. CreativeOne Wealth LLC raised its stake in Amgen by 3.7% in the third quarter. CreativeOne Wealth LLC now owns 15,904 shares of the medical research company’s stock valued at $4,488,000 after purchasing an additional 566 shares in the last quarter. Finally, Natixis Advisors LLC raised its stake in Amgen by 0.7% in the third quarter. Natixis Advisors LLC now owns 341,057 shares of the medical research company’s stock valued at $96,246,000 after purchasing an additional 2,403 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

AMGN has been the topic of a number of analyst reports. Leerink Partners reiterated a “market perform” rating and set a $355.00 price objective on shares of Amgen in a research note on Thursday. Sanford C. Bernstein cut shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 target price for the company. in a research report on Tuesday, January 20th. Barclays began coverage on shares of Amgen in a report on Friday, February 20th. They set an “equal weight” rating and a $350.00 price target for the company. Rothschild & Co Redburn lifted their price objective on shares of Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a research note on Wednesday, February 18th. Finally, Citigroup boosted their price objective on shares of Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a research report on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Amgen presently has an average rating of “Hold” and an average price target of $354.17.

Amgen Stock Up 0.5%

Shares of NASDAQ AMGN opened at $369.53 on Friday. The company has a market cap of $199.20 billion, a price-to-earnings ratio of 25.97, a PEG ratio of 3.67 and a beta of 0.45. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $391.29. The stock has a 50-day moving average price of $353.26 and a two-hundred day moving average price of $322.62.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The company had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same period last year, the company posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be given a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 2.7%. Amgen’s dividend payout ratio (DPR) is currently 70.84%.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen’s recent quarter beat revenue and EPS estimates and management issued FY‑2026 EPS guidance, which supports the buy thesis and helped lift sentiment. Why Is Amgen (AMGN) Up 3.6% Since Last Earnings Report?
• Positive Sentiment: The board declared a $2.52 quarterly dividend (ex‑dividend May 15), reinforcing shareholder returns and supporting income‑oriented demand for the stock. AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND
• Neutral Sentiment: Amgen will present at the Leerink Partners 2026 Global Healthcare Conference (Mar 11). The fireside chat with the CFO and rare‑disease head could provide more detail on pipeline priorities and capital allocation — a potential catalyst depending on the tone. AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE
• Neutral Sentiment: Short‑interest data reported for early March appears to show no meaningful short position (entries list zeros/NaN), which suggests short sellers are not a large immediate pressure point — note the data may reflect reporting quirks.
• Negative Sentiment: Amgen and partner Kyowa Kirin halted all rocatinlimab trials after safety signals linking OX40 pathway modulation to malignancies. Losing a late‑stage immunology asset is a clear pipeline setback and could reduce upside from future launches. Amgen Faces Rocatinlimab Halt And Rethinks Pipeline And Capital Priorities
• Negative Sentiment: Senate Democrats are pressing pharma companies over pricing deals tied to the prior administration, raising the risk of increased political and regulatory scrutiny that could pressure margins or pricing for large biopharma firms including Amgen. Pharma giants pressed by Senate Democrats over Trump pricing deals
• Negative Sentiment: At least one analyst piece has downgraded the stock to a “hold” / advised waiting for a better entry point, signaling some caution on valuation after the recent run. Amgen: Wait For A Better Entry Point (Rating Downgrade)

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.